BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front....
BC Week In Review | Sep 14, 2018
Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...
BC Week In Review | Sep 13, 2018
Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised $100 million on Sept. 6 via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and SunTrust Robinson Humphrey. The price...
BC Extra | Sep 7, 2018
Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
BC Week In Review | Apr 27, 2018
Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said on April 20 it has resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In 2015, Alnylam filed a suit...
Company News | Apr 20, 2018
Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing....
BC Week In Review | Dec 15, 2017
Financial News

Dicerna raises $40M in follow-on

RNA therapeutics play Dicerna (NASDAQ:DRNA) raised $40 million through the sale of 5.7 million shares at $7 in a follow-on underwritten by Stifel, Evercore ISI, H.C. Wainwright and SunTrust. The price is an 11% discount...
BC Week In Review | Aug 18, 2017
Company News

Dicerna sues Alnylam for alleging misappropriation of trade secrets

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) filed a suit in the U.S. District Court for the District of Massachusetts alleging that Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is using “sham litigation” to “thwart Dicerna’s competitive business activities and illegally...
Items per page:
1 - 9 of 9